• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

    11/7/22 1:32:39 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RPID alert in real time by email
    SC 13G/A 1 Rapid_Micro_Biosystems_Inc.htm FILING RAPID MICRO BIOSYSTEMS, INC. Schedule 13G


     
    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 01)*
     
    Rapid Micro Biosystems, Inc. 

    (Name of Issuer)
     
    Class A common stock, $0.01 par value per share

    (Title of Class of Securities)
     
    75340L104

    (CUSIP Number)
     
    October 31, 2022

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         x  Rule 13d-1(b)
     
         o  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  75340L104            
     
               
    1   NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
      JPMORGAN CHASE & CO.

    13-2624428
         
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)



      (a)   o
      (b)   o
         
    3   SEC USE ONLY
       
       
         
    4   CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware
           
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:  5   SOLE VOTING POWER
       
      1,246,582
         
    6   SHARED VOTING POWER
       
      0
         
    7   SOLE DISPOSITIVE POWER
       
      1,403,862
         
    8   SHARED DISPOSITIVE POWER
       
      0
         
    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      1,403,862
         
    10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      o
         
    11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      3.8 %
         
    12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      HC
     

    FOOTNOTES
       
     
     
     

     
     
    Item 1.


     
    (a)
    Name of Issuer
     
     
    Rapid Micro Biosystems, Inc.


     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    1001 Pawtucket Boulevard West, Suite 280
    Lowell, MA 01854


    Item 2.


     
    (a)
    Name of Person Filing
     
     
    JPMORGAN CHASE & CO.


     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    383 Madison Avenue
    New York, NY 10179


     
    (c)
    Citizenship
     
     
    Delaware


     
    (d)
    Title of Class of Securities
     
     
    Class A common stock, $0.01 par value per share


     
    (e)
    CUSIP Number
     
     
    75340L104


     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:


     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).


     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).


     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).


     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).


     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);


     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);


     
    (g)
    x
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);


     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).


     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.


     
    (a)
    Amount beneficially owned: 1,403,862


     
    (b)
    Percent of class: 3.8 %


     
    (c)
    Number of shares as to which the person has:


     
    (i)
    Sole power to vote or to direct the vote: 1,246,582


     
    (ii)
    Shared power to vote or to direct the vote: 0


     
    (iii)
    Sole power to dispose or to direct the disposition of: 1,403,862


     
    (iv)
    Shared power to dispose or to direct the disposition of: 0


    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x .
     
     
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    Not Applicable
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    J.P. Morgan Investment Management Inc.
    JPMorgan Chase Bank, National Association
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Not Applicable
     
    Item 9.
    Notice of Dissolution of Group
     
    Not Applicable
     
     
     

     
     
     
    Item 10.
    Certification
       
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     


    SIGNATURE


    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
      JPMORGAN CHASE & CO.

     
           
    Date: November 07, 2022
    By:
    /s/  Rachel Tsvaygoft  
        Name: Rachel Tsvaygoft  
        Title:  Vice President  
           
     
    Footnotes:


    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     



    Get the next $RPID alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RPID

    DatePrice TargetRatingAnalyst
    2/12/2025$8.00Overweight
    KeyBanc Capital Markets
    8/16/2022Overweight → Neutral
    JP Morgan
    3/7/2022$11.00 → $10.00Equal-Weight
    Morgan Stanley
    2/15/2022$24.00 → $11.00Equal-Weight
    Morgan Stanley
    11/15/2021$26.00 → $24.00Equal-Weight
    Morgan Stanley
    8/9/2021Outperform
    Cowen
    8/9/2021$26.00Equal-Weight
    Morgan Stanley
    8/9/2021$28.00Buy
    Stifel
    More analyst ratings

    $RPID
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pei Melinda Litherland bought $20,364 worth of shares (20,000 units at $1.02), increasing direct ownership by 58% to 54,300 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      12/5/24 6:44:47 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Pei Melinda Litherland bought $20,999 worth of shares (20,000 units at $1.05), increasing direct ownership by 140% to 34,300 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      11/27/24 9:42:03 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Malloy Kirk bought $45,335 worth of shares (50,000 units at $0.91), increasing direct ownership by 350% to 64,300 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      8/9/24 8:36:24 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rapid Micro Biosystems Reports First Quarter 2025 Financial Results

      Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly service revenue led by strong validation activity. Reports first quarter gross margin of 6%, representing a 33-percentage point improvement compared to the first quarter of 2024.Announced a global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma ("MilliporeSigma"). Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Compa

      5/9/25 7:00:55 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems to Announce First Quarter 2025 Financial Results on May 9, 2025

      LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2025 financial results prior to the market open on Friday, May 9, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, May 9, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for replay after

      4/24/25 4:15:32 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants (i) on March 3, 2025, of 50,000 restricted stock units ("RSUs") of the Company's Class A common stock ("Common Stock") as a material inducement to employment of one new employee and (ii) on March 10, 2025, of non-qualified stock options to purchase an aggregate of 250,000 shares of Common Stock (the "Options") and 174,000 RSUs as a material inducement to employment to two

      3/12/25 4:30:02 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • KeyBanc Capital Markets initiated coverage on Rapid Micro Biosystems with a new price target

      KeyBanc Capital Markets initiated coverage of Rapid Micro Biosystems with a rating of Overweight and set a new price target of $8.00

      2/12/25 7:09:40 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems downgraded by JP Morgan

      JP Morgan downgraded Rapid Micro Biosystems from Overweight to Neutral

      8/16/22 7:57:15 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Morgan Stanley reiterated coverage on Rapid Micro Biosystems with a new price target

      Morgan Stanley reiterated coverage of Rapid Micro Biosystems with a rating of Equal-Weight and set a new price target of $10.00 from $11.00 previously

      3/7/22 8:37:27 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Financials

    Live finance-specific insights

    See more
    • Rapid Micro Biosystems Reports First Quarter 2025 Financial Results

      Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly service revenue led by strong validation activity. Reports first quarter gross margin of 6%, representing a 33-percentage point improvement compared to the first quarter of 2024.Announced a global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma ("MilliporeSigma"). Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Compa

      5/9/25 7:00:55 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems to Announce First Quarter 2025 Financial Results on May 9, 2025

      LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2025 financial results prior to the market open on Friday, May 9, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, May 9, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for replay after

      4/24/25 4:15:32 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance

      Reports record fourth quarter 2024 total revenue of $8.2 million, representing 30% growth compared to fourth quarter 2023; recurring revenue increased by 27% compared to the fourth quarter of 2023.Announces full year 2024 total revenue of $28.1 million, representing 25% growth compared to 2023; recurring revenue increase by 14% compared to 2023.Reports record fourth quarter gross margin of 12%, representing a 15-percentage point improvement over the fourth quarter of 2023; full year 2024 gross margin increased 24 percentage points compared to 2023.Announces global Distribution and Collaboration Agreement with MilliporeSigma LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro

      2/28/25 6:30:13 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Leadership Updates

    Live Leadership Updates

    See more
    • Rapid Micro Biosystems Announces Appointment of Kirk Malloy, Ph.D. as Chair of its Board of Directors

      LOWELL, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Kirk Malloy, Ph.D. as Chair of the Company's Board of Directors (the "Board"). Dr. Malloy will also Chair the Board's Compensation Committee. Jeffrey Schwartz, who previously served as Board Chair, remains a member of the Board and continues to serve as Chair of the Nominating and Corporate Governance Committee. "We are very excited to welcome Kirk to our Boar

      7/18/23 5:20:56 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Announces the Appointment of Michael Wysocki as Senior Vice President, Sales and Marketing

      LOWELL, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Michael Wysocki to the position of Senior Vice President, Sales and Marketing. Wysocki joins the Company with nearly two decades of experience at General Electric and GE Healthcare. During his GE career, he held roles of increasing responsibility in their imaging, molecular imaging and computed tomography (CT) businesses before becoming the General Manager, U.S

      5/4/23 4:30:10 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Reaction Biology Announces Appointment of Richard S. Kollender to Chief Financial Officer and Chief Business Officer

      MALVERN, Pa., April 4, 2022 /PRNewswire/ -- Reaction Biology ("Reaction" or the "Company"), an industry-leading provider of drug discovery services, today announced the appointment of Richard S. Kollender to the positions of Chief Financial Officer (CFO), Chief Business Officer (CBO) and member of the Executive Committee, effective immediately, to further strengthen the leadership team and support the Company's next stage of growth. "We are thrilled to welcome Rich, a seasoned healthcare finance and operations executive, to the Executive Committee of Reaction Biology," said John H. Johnson, Chief Executive Officer and Director of Reaction Biology.  "Having managed large, global biopharmaceut

      4/4/22 9:30:00 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    SEC Filings

    See more
    • SEC Form 10-Q filed by Rapid Micro Biosystems Inc.

      10-Q - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

      5/9/25 4:21:23 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

      5/9/25 7:06:07 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Rapid Micro Biosystems Inc.

      DEFA14A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

      4/8/25 4:53:08 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

      SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

      2/14/24 10:04:40 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

      SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

      1/22/24 5:28:26 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

      SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

      2/14/23 4:17:23 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Spignesi Robert G. Jr. covered exercise/tax liability with 10,650 shares, decreasing direct ownership by 1% to 872,366 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      3/11/25 7:19:38 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • CHIEF FINANCIAL OFFICER Wirtjes Sean M covered exercise/tax liability with 7,690 shares, decreasing direct ownership by 2% to 489,955 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      3/11/25 7:18:44 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • CHIEF OPERATING OFFICER Wilson John J. Addington covered exercise/tax liability with 9,872 shares, decreasing direct ownership by 4% to 232,474 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      3/11/25 7:17:20 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials